-

Forge Biologics to Present at Jefferies Gene Therapy / Editing Summit

COLUMBUS, Ohio--(BUSINESS WIRE)--Forge Biologics, a gene therapy-focused contract development and manufacturing organization, announced today that Timothy J. Miller, Ph.D., Forge’s CEO, President, and Co-Founder, will deliver a company presentation at the Jefferies Gene Therapy / Editing Summit on Thursday, October 28, at 12:30 p.m. ET.

The conference will take place October 27-28, 2021 virtually. A live replay of the presentation will be available on the Jefferies conference website for 30 days following the presentation: https://wsw.com/webcast/jeff208/forge/1993455.

The Forge Biologics leadership team, including Dr. Miller; John Maslowski, Chief Commercial Officer; Christina Perry, Vice President of Finance and Investor Relations; and Magdalena Tyrpien, Vice President and Head of Business Development, will be available for 1:1 meetings virtually throughout the conference.

About Forge Biologics

Forge Biologics is a hybrid gene therapy contract manufacturing and therapeutics development company. Forge’s mission is to enable access to life changing gene therapies and help bring them from idea to reality. Forge has a 175,000 square foot facility in Columbus, Ohio, The Hearth, to serve as its headquarters. The Hearth is a custom-designed cGMP facility dedicated to AAV vector manufacturing and will host end-to-end manufacturing services to accelerate gene therapy programs from preclinical through clinical and commercial stage manufacturing. By taking a patients-first approach, Forge aims to accelerate the timelines of these transformative medicines for those who need them the most. To learn more, visit www.forgebiologics.com.

Contacts

Media Inquiries
Marina Corleto
Senior Manager, Marketing and Communications
media@forgebiologics.com

Families and Clinician Inquiries
Dr. Maria Escolar
Chief Medical Officer
medicalaffairs@forgebiologics.com

Business Development
Magdalena Tyrpien
Vice President, Head of Business Development
BD@forgebiologics.com

Client Development
John Maslowski
Chief Commercial Officer
CD@forgebiologics.com

Investor Relations
Christina Perry, MSA, CPA
Vice President, Finance and Investor Relations
Investors@forgebiologics.com

Forge Biologics


Release Summary
Forge Biologics to Present at Jefferies Gene Therapy Editing Summit
Release Versions
Hashtags

Contacts

Media Inquiries
Marina Corleto
Senior Manager, Marketing and Communications
media@forgebiologics.com

Families and Clinician Inquiries
Dr. Maria Escolar
Chief Medical Officer
medicalaffairs@forgebiologics.com

Business Development
Magdalena Tyrpien
Vice President, Head of Business Development
BD@forgebiologics.com

Client Development
John Maslowski
Chief Commercial Officer
CD@forgebiologics.com

Investor Relations
Christina Perry, MSA, CPA
Vice President, Finance and Investor Relations
Investors@forgebiologics.com

Social Media Profiles
More News From Forge Biologics

Skylark Bio and Forge Biologics Announce Strategic AAV Development and cGMP Manufacturing Partnership Supporting Skylark’s Clinical Development

CAMBRIDGE, Mass. & COLUMBUS, Ohio--(BUSINESS WIRE)--Skylark Bio (“Skylark”), a clinical-stage biotechnology company developing targeted genetic medicines for hearing loss, and Forge Biologics (“Forge”), a leading manufacturer of gene therapies and member of Ajinomoto Bio-Pharma Services, today announced a strategic AAV development and cGMP manufacturing partnership. Under the partnership, Forge is providing Skylark with process development, current good manufacturing practice (cGMP) manufacturi...

Forge Biologics Announces Seven Presentations at the American Society of Gene and Cell Therapy (ASGCT) 29th Annual Meeting

COLUMBUS, Ohio--(BUSINESS WIRE)--Forge Biologics, (“Forge”), a leading manufacturer of gene therapies and member of the Ajinomoto Bio-Pharma Services group, today announced that it will deliver seven presentations at the upcoming American Society of Gene and Cell Therapy (ASGCT) 29th Annual Meeting, taking place May 11-15, 2026, in Boston. The presentations include two technical sessions, co-chairing an oral abstract session, and four scientific posters. “As the gene therapy field enters a crit...

Epicrispr Biotechnologies and Forge Biologics Announce AAV Development and cGMP Manufacturing Partnership

SAN FRANCISCO & COLUMBUS, Ohio--(BUSINESS WIRE)--Epicrispr Biotechnologies (“Epicrispr”), a clinical-stage company pioneering gene-modulating therapies, and Forge Biologics (“Forge”), a leading manufacturer of gene therapies and member of the Ajinomoto Bio-Pharma Services group, today announced a strategic partnership to support the development and manufacturing of EPI-321, Epicrispr’s investigational AAV gene therapy for facioscapulohumeral muscular dystrophy (FSHD). Through this collaboration...
Back to Newsroom